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effective depression treatments, the majority of people with type 2 diabetes do not access these when 
needed. Web-based alternatives to more traditional psychotherapies offer a potential solution to reducing 
the personal and economic burdens of type 2 diabetes. Objective: This paper outlines the protocol for a 
randomized controlled trial (RCT) of myCompass, a Web-based public health psychotherapy intervention, 
in people with type 2 diabetes. Fully automated, interactive, and delivered via the Internet without clinician 
support, myCompass teaches cognitive behavioral therapy-based skills and supports symptom 
monitoring to improve daily functioning and reduce mild-to-moderate mental health symptoms. Methods: 
A two-arm RCT will be conducted. People with type 2 diabetes and mild-to-moderately severe depressive 
symptoms will be recruited from the community and general practice settings. Screening and enrollment 
is via an open-access website. Participants will be randomized to use either myCompass or an active 
placebo program for 8 weeks, followed by a 4-week tailing-off period. The placebo program is matched to 
myCompass on mode of delivery, interactivity, and duration. Outcomes will be assessed at baseline and at 
3-month, 6-month, and 12-month follow-up. The primary study outcome is work and social functioning. 
Secondary study outcomes include depressive and anxious symptoms, diabetes-related distress, self-
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This is the first known trial of a Web-based psychotherapy program that is not diabetes specific for 
improving social and vocational function in people with type 2 diabetes and mild-to-moderately severe 
depressive symptoms. With the increasing prevalence of type 2 diabetes and depression, a potentially 
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Abstract
Background: Depressive symptoms are common in people with type 2 diabetes and contribute to adverse health consequences
that substantially impact social and vocational function. Despite the existence of effective depression treatments, the majority of
people with type 2 diabetes do not access these when needed. Web-based alternatives to more traditional psychotherapies offer
a potential solution to reducing the personal and economic burdens of type 2 diabetes.
Objective: This paper outlines the protocol for a randomized controlled trial (RCT) of myCompass, a Web-based public health
psychotherapy intervention, in people with type 2 diabetes. Fully automated, interactive, and delivered via the Internet without
clinician support, myCompass teaches cognitive behavioral therapy-based skills and supports symptom monitoring to improve
daily functioning and reduce mild-to-moderate mental health symptoms.
Methods: A two-arm RCT will be conducted. People with type 2 diabetes and mild-to-moderately severe depressive symptoms
will be recruited from the community and general practice settings. Screening and enrollment is via an open-access website.
Participants will be randomized to use either myCompass or an active placebo program for 8 weeks, followed by a 4-week
tailing-off period. The placebo program is matched to myCompass on mode of delivery, interactivity, and duration. Outcomes
will be assessed at baseline and at 3-month, 6-month, and 12-month follow-up. The primary study outcome is work and social
functioning. Secondary study outcomes include depressive and anxious symptoms, diabetes-related distress, self-care behaviors,
and glycemic control.
Results: Nationwide recruitment is currently underway with the aim of recruiting 600 people with type 2 diabetes. Recruitment
will continue until October 2017.
Conclusions: This is the first known trial of a Web-based psychotherapy program that is not diabetes specific for improving
social and vocational function in people with type 2 diabetes and mild-to-moderately severe depressive symptoms. With the
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increasing prevalence of type 2 diabetes and depression, a potentially scalable public health intervention could play a very large
role in reducing unmet mental health need and ameliorating the personal and societal impact of illness comorbidity.
Trial Registration: Australian New Zealand Clinical Trials Registry (ANZCTR) Number: ACTRN12615000931572;
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368109 (Archived by WebCite at http://www.webcitation.org/
6rh3imVMh)
(JMIR Res Protoc 2017;6(8):e145)   doi:10.2196/resprot.7348
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Introduction
Background
Type 2 diabetes is a common chronic and disabling disease and
a major contributor to global disease burden [1]. Depression is
frequently comorbid with type 2 diabetes and contributes
independently to a range of adverse health outcomes that
substantially compromise social and vocational functioning.
These include greater diabetes symptom burden, poorer
self-care, and increased risk of micro- and macrovascular
complications and mortality [2]. In addition, the economic
impact of disease comorbidity is considerable with functional
disability, functional dependence, workplace productivity losses,
health service use, and health care costs higher for people with
both conditions than those with diabetes alone [2,3].
Research supports a bidirectional relationship between type 2
diabetes and depression [4]. Findings supporting increased risk
of type 2 diabetes in people with depression [5] are generally
explained with reference to physiological (eg, hypothalamic-
pituitary-adrenal axis dysfunction [6]), motivational (eg, poorer
self-care, adiposity, and inactivity [6,7]), and/or pharmacologic
(eg, impact of antidepressant medication on glycemic control
[5]) factors. At the same time, increased risk of depression in
people with type 2 diabetes is generally attributed to the
emotional burden of living with a complex and demanding
disease that often intrudes into normal lifestyle [8]. The
likelihood of a reciprocal relationship between type 2 diabetes
and depression makes the personal and societal impact of illness
comorbidity potentially immeasurable [4].
Despite the existence of evidence-based therapies for depression
in diabetes, including cognitive behavioral therapy (CBT) and
antidepressant medication, upward of 60% of people with
comorbid conditions do not receive mental health treatment [9].
In the primary health care setting, where most people with type
2 diabetes access medical treatment, low screening rates mean
that depressive symptoms are often missed [9] and only a
minority of patients who screen positive accept a referral for
face-to-face support [10]. At the same time, personal, social,
and structural barriers to seeking help—including privacy
concerns and stigma, lack of support and poor relationships
with health care providers, time and lifestyle constraints,
financial cost, and lack of service availability—compromise
access to satisfactory mental health care for many patients
[11,12]. There is considerable opportunity, therefore, to reduce
the personal and societal burden of illness by facilitating greater
access to more flexible and cost-efficient mental health
treatments for this patient group.
Internet delivery of evidence-based psychological therapies is
a popular, clinically effective, and cost-effective means of
increasing treatment reach; a small number of Web-based
diabetes-specific interventions that directly target depression
have been evaluated [13]. These include van Bastelaar et al’s
[14] adaptation of Lewinsohn’s Coping with Depression
Program and Nobis et al’s [15] application of systematic
behavioral activation and problem-solving therapy (ie,
GesundheitsTraining.Online Mood Enhancer Diabetes [GET.ON
MED]). Findings from these studies establish the symptom
benefits of Internet-delivered self-help for diabetes patients with
clinically relevant levels of depressive symptomatology.
However, subthreshold depression is more prevalent in type 2
diabetes than clinical depression and is associated with increased
functional limitation and disability, including reduced social
and vocational performance [16,17]. As such, the effectiveness
of electronically delivered psychotherapy as a treatment
approach for type 2 patients with mild-to-moderate depressive
symptoms also warrants rigorous scientific attention.
Proudfoot et al [18] have previously published controlled data
showing that mild-to-moderate mental health symptoms—
including symptoms of depression, anxiety, and stress—are
reduced following use of the broadly available Web-based
program, myCompass, with treatment benefits extending to
work and social functioning. More recently, in an uncontrolled
pilot study, myCompass showed promise as an acceptable and
effective treatment for depression and functional disability in
people with type 1 and type 2 diabetes [19]. myCompass differs
from the interventions described in van Bastelaar et al [14] and
Nobis et al [15] in that it is a fully automated (ie, no therapist
input) public health program that is generic in its therapeutic
content (ie, not diabetes sensitive). An intervention approach
that is capable of treating depressive symptoms without
disease-specific modification is potentially a more efficient and
accessible alternative to meeting the unmet mental health needs
of people with type 2 diabetes. Generic skills may also assist
the increasing number of individuals experiencing
multi-morbidity, for whom depression co-occurs with somatic
symptoms of multiple illnesses (eg, diabetes, heart disease,
hypertension, and kidney disease) [20,21]. From a primary care
perspective, a public health program may have important
pragmatic advantages in the primary care setting, where time
pressures often impede dissemination of, and prohibit
practitioner training in, multiple disease-specific tools, and
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where treatment of multi-morbidity and undifferentiated physical
and mental health symptoms is particularly relevant.
Objectives
This paper was prepared using the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) guidance
for presenting clinical trial protocols [22] and the Consolidated
Standards of Reporting Trials of Electronic and Mobile HEalth
Applications and onLine TeleHealth (CONSORT-EHEALTH)
checklist [23]. The paper describes a randomized controlled
trial (RCT) of the Web-based intervention, myCompass, in
patients with comorbid type 2 diabetes and mild-to-moderately
severe depressive symptoms. The primary aim of this RCT,
called SpringboarD, is to determine whether treatment with
myCompass improves work and social function for people with
type 2 diabetes and mild-to-moderate depressive symptoms. As
functional disability predicts further functional deterioration,
functional dependence, and increased use of health services and
health care costs [16], depression treatments that improve work
and social functioning may substantially reduce the personal
and economic burden of comorbid depression and type 2
diabetes. Specifically, we hypothesize that the intervention
group will show significant improvement in self-reported
functioning socially and in the workplace compared with a
placebo-controlled condition.
Our secondary aim is to evaluate the impact of myCompass on
a range of symptom- and disease-related variables known to
impact a patient’s disease management and blood glucose
control. Specifically, in addition to depressive symptoms, we
will examine whether myCompass is more effective than a
placebo condition in improving anxiety symptoms and
diabetes-related distress. Defined as a person’s emotional
adjustment to the chronic stressors specific to diabetes,
diabetes-related distress is of particular interest due to its greater
prevalence and potential role in mediating the relationship
between depression and glycemic control [24]. While we have
preliminary evidence suggesting that diabetes-related distress
may improve following treatment with myCompass [19],
replication of this finding in a controlled study is required.
Trial Design
The study is designed as a two-arm individually randomized
RCT and is conducted entirely online. Participants allocated to
the intervention group have full access to the myCompass
program for 8 weeks, followed by a 4-week tailing-off period
to facilitate maintenance. Participants randomized to the control
group have access to a placebo Internet-delivered program that
is matched to myCompass on mode and duration of delivery
and interactivity, but is void of therapeutic content. Participants
in both groups have uninterrupted access to treatment as usual
for their diabetes during the study.
Methods
Participants, Interventions, and Outcomes
Study Setting
The setting for this study is Australia. An estimated 1 million
Australian adults—5% of the population—had self-reported
type 2 diabetes in September 2016, and rates are similar across
metropolitan, regional, and remote areas [25].
Eligibility Criteria
This study focuses on adults with type 2 diabetes and
mild-to-moderately severe depressive symptoms. People are
eligible to take part if they are aged 18-75 years, screen positive
for depression on the 2-item Patient Health Questionnaire
(PHQ-2) (ie, score ≥2) [26], and have access to an
Internet-enabled device (eg, computer, tablet, and/or mobile
phone). People who screen positive for depression complete the
full 9-item Patient Health Questionnaire (PHQ-9) at screening
so that the level of symptom severity can be determined.
Exclusion criteria include inability to read English with ease,
severe depressive symptoms on the full PHQ-9 (ie, score >19),
probable psychosis as measured by the psychosis screener
developed for the Australian National Mental Health and
Wellbeing Survey [27], currently receiving face-to-face
counseling or therapy for depression, changed antidepressant
medication in the previous 2 months, high suicide risk as
assessed by item 9 of the PHQ-9, and previous use of the
myCompass program.
Interventions
Active Intervention
The active intervention, myCompass [28], is a fully automated,
self-help, public health intervention that is tailored to the user
and has no therapist involvement in its delivery. Program
tailoring occurs via users’ responses to a symptom profiler
completed at registration. In-built algorithms target the user’s
most salient symptoms and provide recommendations about the
symptoms and/or behaviors they might consider monitoring and
the treatment modules likely to be of greatest therapeutic benefit.
There is flexibility, however, for users to choose their own set
of self-monitoring dimensions and treatment modules (see
Figures 1-4).
Self-monitoring of symptoms and lifestyle factors occurs in real
time via mobile (eg, phone or tablet) and stationary (eg, desktop
computer) devices. Users can self-monitor up to three symptoms
and behaviors of their choice at any one time—selected from a
list of 20—or three that are recommended to them by the
program. Each symptom is rated on a 10-point scale. At the
time of rating, users also provide contextual information about
where they are, what they are doing, and who they are with
using a series of drop-down menus. Users can schedule short
message service (SMS) text message or email reminders to
facilitate self-monitoring—frequency of reminders is determined
by the user; receive and print graphical feedback about their
monitoring, including contextual information, on their phone
or computer to monitor change and assist identification of
triggers; and elect to receive helpful facts, mental health care
tips, or motivational statements by SMS text message or email.
myCompass treatment modules were developed by mental health
professionals at the Black Dog Institute in Sydney, Australia.
The program contains 14 skill-building modules derived from
CBT, interpersonal psychotherapy, problem-solving therapy,
and positive psychology that are interactive and available for
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completion on computer and tablet devices. Module content
covers topics such as Managing Fear and Anxiety, Tackling
Unhelpful Thinking, Managing Loss and Major Life Change,
and Solving Problems. Each module comprises three 10-minute
sessions and includes home practice tasks for completion
between the weekly sessions to promote skill generalization.
The module targeting stress in diabetes has been deactivated
for trial participants, to ensure that the intervention is a generic
public health program. Participants are encouraged to complete
at least three modules during the intervention period, during
their own time.
User privacy is managed by a password-protected log-on and
by ensuring that user-generated data (ie, self-monitoring ratings)
are not stored on the user’s phone, but are instead transferred
via the Internet using Secure Sockets Layer protocol, which
encrypts transmitted data by rendering it unreadable to anyone
other than the intended recipient, and by storing the data in
secure servers. The data is reidentifiable only with the list of
study participant codes, to which only the named researchers
will have access and which will be stored in a
password-protected file separate from the study data. Registering
to use myCompass is free and users are not billed for the SMS
text messages they receive.
Participants randomized to myCompass have access to the full
program for 8 weeks, followed by a 4-week tailing-off period
during which only the symptom-monitoring function will be
accessible. Research has shown that adherence with online
interventions is improved when users receive program feedback
that is personalized in its content [29]. For this reason,
myCompass users receive automated personalized feedback via
email about their use of the program’s self-monitoring and
module functions at fixed intervals (ie, weeks 1, 3, 5, and 7).
Figure 1. Screenshot of myCompass landing page.
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Figure 2. Screenshot of myCompass self-monitoring page.
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Figure 3. Screenshot of a page from the myCompass module Tackling Unhelpful Thinking.
Figure 4. Screenshot of myCompass graphical feedback.
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Placebo Intervention
The placebo program, Healthy Lifestyles, was adapted from a
control program used in previous studies by members of the
research team. Like myCompass, the program offers users
program tailoring at the outset, followed by access to a range
of interactive modules containing health- and lifestyle-related
information, including skin care and eye health. It contains no
therapeutic content, has high face validity as a health and
lifestyle intervention, and has previously shown no symptom
impact [30]. Participants have full access to the placebo
condition for 8 weeks, plus a 4-week tailing-off period (see
Figures 5-7).
To further replicate the interactivity of myCompass, users of
the placebo program receive an email at weeks 1, 3, 5, and 7
containing a brief reminder to log into the program, but no
feedback about their use of the program. They also receive a
weekly email containing a factual statement about a health or
lifestyle issue.
Figure 5. Screenshot of landing page for placebo program, Healthy Lifestyles.
Figure 6. Page from the Healthy Lifestyles module, The Skin You Live In.
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Figure 7. Sample interactive task from the Healthy Lifestyles module.
Table 1. Assessments completed at assessment phases.
Assessment phaseAssessments
T4dT3cT2bT1a
Baseline
XDemographic data
XXXXDisease/treatment data
XMental health history
XXXXWork and Social Adjustment Scale [31]Primary outcome
Secondary outcomes
XXXXPatient Health Questionnaire-9 [26]
XXXXDiabetes Distress Scale [32]
XXXXGeneralized Anxiety Disorder Scale [33]
XXXXSelf-Management Profile for Type 2 Diabetes Scale (behavior items only) [34]
XXXGlycosylated hemoglobin (HbA1c)
XXXXDays out of role [35]
XXXXHealth service utilization
aT1: baseline assessment and allocation to intervention or placebo group.
bT2: completion of intervention period and online postintervention assessment.
cT3: completion of 6-month follow-up assessment.
dT4: completion of 12-month follow-up assessment.
Outcomes
A summary of assessments completed online by participants at
baseline, postintervention, and follow-up is presented in Table
1 [26,31-35].
The primary outcome is work and social functioning, which is
measured by the Work and Social Adjustment Scale (WSAS)
[31]. The WSAS is a psychometrically sound measure of the
impact of mental health problems on daily functioning in five
domains: work, social leisure activities, private leisure activities,
home management, and personal relationships [31,36]. Scores
range from 0 to 40, with higher scores indicating poorer
adjustment.
Secondary outcomes include the PHQ-9, the Diabetes Distress
Scale [32], the 7-item Generalized Anxiety Scale [33], and the
Self-Management Profile for Type 2 Diabetes Scale [34].
At baseline and again at 6- and 12-month follow-up,
glycosylated hemoglobin (HbA1c) data will also be collected
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from participants’ medical records, with their consent. The
HbA1c test is a blood test showing a person's average blood
glucose level over the previous 3 months and is measured as
part of routine clinical care to monitor long-term blood sugar
control in people with diabetes. In all cases, the most recent
result will be obtained.
Additional measurements include collection of disease-related
data (eg, age of onset and treatment regimen), sociodemographic
data (eg, age, gender, education, and occupation), and mental
health history data (eg, service use and previous diagnoses) at
baseline. Service utilization and supports, including medication,
received for problems related to mental health and diabetes are
also assessed at each assessment point. Days out of role are
measured using an item from the World Health Organization
Disability Assessment Schedule that asks people to note the
number of days in the previous 30 that they were completely
unable to perform their work or normal activities because of
problems with their physical or mental health [35].
At the conclusion of the trial, data indicating the extent of
participant engagement with myCompass will be extracted from
the program, including frequency of log-ins, number of modules
started and completed, and self-monitoring frequency.
Participant Timeline
Participant consent, screening, and assessment takes place online
via a secure study-specific website [37]. After providing
informed consent, potential participants complete the online
screening tool to determine eligibility. Unsuitable candidates
receive automated feedback explaining the reason for their
ineligibility; details of crisis supports and other self-help and
face-to-face resources are provided to individuals, as
appropriate.
Eligible candidates are registered in a secure Web-based
platform where they complete the baseline questionnaire and
are immediately allocated randomly to either the intervention
program or control program for a period of 12 weeks.
Subsequent assessment points coincide for both groups at
postintervention (12 weeks) as well as 6 and 12 months after
randomization (see Figure 8).
Sample Size
The primary study outcome is work and social functioning,
which is measured by the WSAS [31]. In a previous study
comparing myCompass with an active control intervention,
Proudfoot et al [18] obtained an average between-group effect
size—based on estimated marginal means—of Cohen d=0.3 for
work and social functioning. We calculated the sample size for
this study using a series of t tests (cross-sectional comparison
of arms) with alpha=.05 and desired power=80%. The sample
size required was N=350 (175 per arm).
We cross-checked the sample size calculation using a reduction
of 5 points on our secondary outcome, the PHQ-9, and got a
similar outcome. A 5-point reduction on the PHQ-9 is considered
an adequate treatment response [26].
Previous studies indicate attrition rates of approximately 40%
in eHealth studies, generally [38]. As such, we aim to recruit
300 participants in each arm of the study (ie, 600 in total) for
sufficient statistical power for completer analyses.
Recruitment
Study participants are being recruited via promotional materials
distributed in general practice settings in New South Wales and
Victoria—where the majority of Australians with type 2 diabetes
reside—and disseminated nationally via print advertisements;
social media posts, including Facebook and Twitter; clinical
research registries; and other publicity channels of state and
local diabetes stakeholder groups and the Black Dog Institute.
Promotional materials invite interested candidates to visit the
SpringboarD Project website [37] to provide consent and
complete the screening tool. The recruitment message for the
study focuses on learning new ways to deal with stress and
distress and live active and emotionally healthier lives with type
2 diabetes. Recruitment has commenced and will continue until
October 2017 or until our sample target is reached.
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Figure 8. SpringboarD participant flow diagram.
Assignment of Interventions
Allocation
We are using computerized blocked randomization with blocks
of eight to assign participants to the two treatment conditions.
Randomization to the intervention and placebo program occurs
immediately after a participant completes the baseline measures
using an automated system built into the study software. In this
way, the allocation sequence is applied without the researchers’
knowledge.
Blinding
The placebo program has been developed to replicate the mode
of delivery, interactivity, and duration of myCompass and
participants in each group will be treated equally by the research
team. It is not possible, however, to assume that participants
will remain blind to study allocation during the intervention and
follow-up periods.
Data Collection, Management, and Analysis
Data Collection
The majority of primary and secondary outcome data is being
collected electronically via standardized self-report
questionnaires that are completed by logging into the
SpringboarD study website (described above). At each
assessment point, the website sends a unique link to the study
questionnaire via email. Questionnaire data is maintained on a
secure server at the University of New South Wales (UNSW)
Sydney and is downloaded periodically for storage in a
password-protected data file accessible by two project personnel
(JC and SS). HbA1c data is collected from each participant’s
general practitioner (GP) via phone, mail, and/or facsimile.
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Retention
Participant attrition is a major concern in studies of unguided
interventions [38]. To facilitate trial retention, we are utilizing
a combination of strategies covering various themes that have
been used with success in previous studies. First, a systematic
schedule of push messages, including personalized email and
telephone prompts and reminders, is being implemented to
motivate questionnaire completion at each of the
postintervention and follow-up assessments [39]. Second, Aus
$30 gift vouchers are provided to participants who return
completed questionnaires at each time point to compensate them
for the time and effort they have expended [40]. Third, a sense
of project identity is maintained by using a study logo and design
template (ie, set fonts, formatting, and colors) to create the
SpringboarD brand, and by distributing quarterly newsletters
to participants to update them on trial progress [41]. Finally, a
phone call from the research team within a week of registration
provides participants a minimum level of human contact and
the team an opportunity to express thanks, provide
encouragement, and confirm personal details [42].
Statistical Analysis
Participants in the intervention and control groups will be
compared at baseline using chi-square tests for categorical data
and t tests for continuous data to assess randomization success.
Treatment effects on primary and secondary outcomes will be
evaluated by intention-to-treat analysis using mixed-models
repeated measures (MMRM). In MMRM, no participant is
removed from the analysis because all available data are used
to obtain parameter estimates. Effect size will be measured using
Cohen d. For all outcome measures, within- and between-group
differences will be standardized to Cohen d using the pooled
standard deviation of the observed scores obtained at baseline.
We plan to analyze contrasts between intervention and control
groups at postintervention and at 3-month, 6-month, and
12-month follow-up.
Supplementary analyses will use data for completers and will
also investigate whether there are any differences by recruitment
source, duration of diabetes, and presence of comorbid
conditions.
Monitoring
The integrity of the trial, including data collection and
monitoring, trial progress, adverse events, and compliance with
UNSW Sydney Human Research Ethics Committee (HREC)
reporting procedures, is overseen by the Steering Committee
consisting of the chief (JP) and associate investigators. The
Steering Committee will meet biannually over the lifespan of
the project. Adverse events may include unfavorable changes
to mental health or diabetes control and may be related or
unrelated to the study. As the study does not impact routine
diabetes care and is examining the effect of an evidence-based
intervention for people with mild-to-moderately severe
depression (ie, serious mental illness is an exclusion criteria),
no serious adverse events are anticipated and no interim analyses
are planned.
Ethics and Dissemination
Research Ethics Approval
The SpringboarD study protocol and materials have been
approved by the HREC at UNSW Sydney and registered with
the Australia and New Zealand Clinical Trials Register
(ACTRN12615000931572). Annual reports and substantive
amendments to this protocol will be submitted to the HREC for
approval by the chief investigator. The study coordinator (JC)
is responsible for communicating protocol changes to relevant
stakeholders, including the Australian New Zealand Clinical
Trials Registry.
Consent or Assent
Information about the study is provided on the SpringboarD
project website; individuals can choose to read the information
online or download a PDF to keep. Consent is obtained online
in a two-stage process. First, individuals consent to the study
by checking a box at the end of the study information page and
progressing to the page containing the eligibility screen. Eligible
individuals are then provided the option of registering an account
with the study website (ie, username and password); those who
opt not to register are also considered to have not consented to
the trial.
Participants consent to the project team informing their treating
GP of his or her involvement in the study to facilitate HbA1c
data collection; they also provide a point of emergency contact
should a participant score in the severely distressed range of
the PHQ-9 (ie, score >19) or be at risk of self-harm (ie, score
3 on item 9 of the PHQ-9) at any assessment point. GPs are
informed by mail within 2 weeks of their patient’s enrolment,
at which time they are requested to inform the research team if
a diagnosis of type 2 diabetes has not been given.
Confidentiality
The eligibility screen is conducted anonymously such that no
personal information about potential participants is collected.
Only eligible individuals provide identifying information that
is downloaded and stored separately from study data in a
password-protected file.
Ancillary and Posttrial Care
At the conclusion of the trial, the active intervention will be
made available to all participants in the control group.
Results
Nationwide recruitment is currently underway with the aim of
recruiting 600 people with type 2 diabetes. Recruitment will
continue until October 2017.
Discussion
Principal Findings
Treatment of depressive symptoms in people with type 2
diabetes might help to improve short- and long-term social and
vocational functioning. Internet-delivered psychotherapy is an
effective treatment for depression in people with type 2 diabetes;
however, few studies have focused on mild-to-moderately severe
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depressive symptoms where treatment need in diabetes patients
is greatest. Rarely has social and vocational function been
evaluated in studies of online depression treatments in type 2
diabetes; the effectiveness of a generic Internet-based program
has not been studied in this patient group. This study will shed
light on whether an Internet-delivered public health program
has the potential to reduce unmet treatment need and lessen the
personal and societal impact of mild-to-moderately severe
depressive symptoms within the context of type 2 diabetes.
Limitations
Trials of self-guided interventions frequently report high rates
of attrition, including study dropout (ie, questionnaire
noncompletion) and/or disengagement from the program [38].
Study attrition introduces selection bias and potential
misrepresentation of treatment effects. To reduce the impact of
actual participant dropout, we will recruit a substantially larger
sample than is required on the basis of our sample size
calculation. To minimize potential study dropout, we will utilize
a combination of strategies that have been shown to positively
impact retention in previous trials, including email and telephone
prompts and reminders [39], recompense for questionnaire
completion [40], and activities aimed at keeping the study “front
of mind” and engaging for older participants [41,43]. In addition,
so that questionnaire completion is not contingent upon program
use, participants will access the study questionnaire outside the
intervention (ie, via a link sent to a nominated email account).
To maximize program use, automated program reminders will
be sent by email to participants at biweekly intervals [29].
Volunteer bias is another possible weakness of this study, as
our recruitment techniques may yield a sample that is healthier
[44] and more highly motivated to learn new skills and engage
with self-guided therapy. Problems occur, for example, if
participation in our study is reflective of better health and a
broader personal commitment to self-improvement of diabetes
outcomes and daily functioning, as this is likely to result in
within-group changes that are larger than for a less motivated
and more representative sample of type 2 diabetes patients.
However, since myCompass is broadly available for self-referral
and use whenever and wherever people choose, the recruitment
processes are consistent with both the self-help nature of the
intervention and its eventual use in the type 2 diabetes
population.
Conclusions
The personal and economic costs of comorbid type 2 diabetes
and depressive symptoms are substantial. However, the
development of Internet-delivered interventions offers a potential
solution to mitigate these impacts [13-15]. myCompass is a
broadly available and efficacious public health intervention that
can be delivered at minimal cost [45]. It therefore presents itself
as a potentially effective and timely option for reducing unmet
mental health need and ameliorating the personal and societal
impact of co-occurring depression and type 2 diabetes.
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